NCT00189202View on ClinicalTrials.gov

Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

July 1, 2008

Study Completion Date

July 1, 2008

Conditions
End Stage Renal DiseaseKidney Transplantation
Interventions
DRUG

Sirolimus

Thymoglobulin induction, sirolimus and no maintenance corticosteroid

Trial Locations (1)

48109

University of Michigan Health Center, Ann Arbor

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

University of Michigan

OTHER

NCT00189202 - Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans | Biotech Hunter | Biotech Hunter